Epilepsy is associated with a high incidence of comorbid neurologic and psychiatric disorders. This review focuses on the association of epilepsy with autism spectrum disorder (ASD) and depression. There is high concordance of these behavioral pathologies with epilepsy. We review data that unambiguously reveal that epilepsy, ASD, and depression are associated with elevated brain inflammatory markers and that these may interact with serotoninergic pathways. Interference with inflammatory pathways or actions can reduce the severity of seizures, depression, and ASD-like behavior. Inflammation in the brain can be induced by seizure activity as well as by behavioral, environmental, and physiologic stressors. Furthermore, induction of inflammation at an early time point during gestation and in early neonatal life can precipitate both an ASD-like phenotype as well as a more excitable brain. It appears likely that priming of the brain due to early inflammation could provide a means by which subsequent inflammatory processes associated with epilepsy, ASD, and depression may lead to comorbidity. KEY WORDS: Autism, Autism spectrum disorder, Depression, Inflammation, Cytokines, Maternal immune activation, Seizures.
Comorbidity appears to be a general feature of disease, but this is especially true for people with epilepsy. For example, there is high co-occurrence of psychiatric and behavioral disorders, 1,2 including cognitive dysfunction 3, 4 and anxiety disorders. 5 It has long been recognized that there is a high concordance of epilepsy and autism spectrum disorder (ASD), 6 and the first focus of this review will explore possible underlying mechanisms. Depression is one of the most common disorders associated with epilepsy, 7, 8 and this and some of its underlying mechanisms will be discussed in more detail later in this short review.
Epilepsy and Autism
(Quentin J. Pittman & Stacy D. Bilbo) Autism or, more correctly, ASD is a complex condition most often diagnosed in childhood that is characterized by deficits in communication and social skills and the presence of repetitive, stereotype behaviors and restricted interests. Recent estimates indicate that its prevalence may be as high as one in 68 children. 9 An association of ASD with epilepsy has long been noted, [10] [11] [12] and recent reports, although highly variable, indicate that anywhere from 5% to 40% of individuals with ASD may have epilepsy, 13, 14 representing an eight-to 20-fold 3, 15 increased odds compared to controls. Some reports indicate that up to two thirds of individuals with ASD may have abnormal EEG activity. 12, 16, 17 There is a large body of literature including many excellent reviews on the subject of epilepsy and ASD, and this brief review is not meant to encompass this body of literature. Rather, a brief overview of salient points is presented to give the reader sufficient background to understand the focus of this article, which is on the contribution of inflammation, especially early life inflammation, to these conditions. Both ASD and epilepsy are associated with a number of abnormalities such as alterations in mini-column architecture and c-aminobutyric acid (GABA) neurotransmission that may alter excitation-inhibition balance. 18, 19 A question that arises is what might account for this comorbid relationship?" Suffice it to say that we do not have an answer for this, but several possibilities exist.
Underlying abnormalities in the brain that exist in ASD may predispose to epilepsy
There have been many studies, both imaging and postmortem, of people, especially children, with ASD. Many studies report structural changes in ASD, especially in the cerebellum and amygdala, but a recent analysis of >500 magnetic resonance imaging (MRI) studies was unable to find consistent replication of many of these structural changes. Nonetheless, there was a consistent trend toward a smaller corpus callosum volume, larger ventricles, and increased thickness in some cortical areas. 20 It is difficult to imagine how altered size of specific structures in the brain might precipitate epilepsy. EEG/functional MRI (fMRI) studies are likely to be more instructive in terms of relating changes here to possible predisposition to seizure-like activity. Although early attention focused on gamma power in the EEG, results here (as well as for other oscillations) were again inconsistent, and a recent review has focused attention rather on intratrial variability to stimuli in the EEG. 21, 22 Both EEG and fMRI studies have also provided convincing evidence of changes in brain connectivity (reviewed in Maximo et al. 23 ). Although these connectivity alterations might be consistent with the difficulties that individuals with ASD have in processing information and their communication difficulties, there is again little evidence to suggest that patterns seen may lead to abnormal synchrony of electrical activity, as seen in epilepsy. Furthermore, there are animal models of ASD that do not exhibit concurrent epilepsy. For example, the inbred Black and Tan Brachyury, Inositol, 1,4,5 triphosphate, tufted mutation/Jackson (BTBR) mouse, which exhibits the hallmark features of ASD, does not display epilepsy 24 (but see below for further discussion of this animal model). Likewise, a well-established developmental model of ASD arising from maternal immune activation has never been reported to show epileptic activity, 25, 26 and when experimental seizures are elicited in this model, ASD like behaviors are actually lessened. 27 Nonetheless, because epileptic-like discharges (partially reversed by valproic acid) were noted in subjects with ASD, 17 even in the absence of diagnosed epilepsy, one might speculate that ASD may be a type of seizure disorder, even if not classified as such. However, if so, it is not well treated by antiseizure medications, as a recent meta-analysis of seven randomized, placebo-controlled trials of antiseizure medications in ASD revealed no differences between medication and placebo in several measured behavioral symptoms. 28 Aberrant brain activity underlying epilepsy may also predispose to ASD A recent, large population-based study 15 identified an increased risk of future ASD in individuals diagnosed with epilepsy, particularly evident if epilepsy was diagnosed in childhood. A 5.5-year interval was reported between diagnosis of epilepsy and ASD, suggesting that epilepsy may predispose to ASD. However, it is important to note that this study excluded anyone with a diagnosis of ASD prior to study entry. Given that ASD is often identified in early childhood, this may represent only a subset of individuals with comorbid epilepsy and ASD. On the other hand, smaller studies where children were diagnosed with new-or recentonset epilepsy and followed for 5-6 years did not detect emergent ASD symptoms. 29 It may also be instructive to examine experimental studies where epilepsy, or at least seizure activity, has been experimentally introduced. For example, when rats were kindled in the amygdala, the major effects seen were changes in fear-or anxiety-related behavior, but no mention of the common behaviors associated with ASD (reviewed in Kalynchuk 30 ). Furthermore, in a phosphatase and tensin homologue (PTEN) haploinsufficient mouse that displays certain ASD features, or in wild types, imposition of a kainic acid-induced seizure did not convincingly cause or exacerbate any of the common features of ASD.
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A common environmental or genetic factor may create a predisposition to both epilepsy and ASD There is a consensus that a common genetic trait may often lead to both epilepsy and ASD. Genetic syndromes, or animal models where these two conditions coexist, include genomic disorders with copy number variants, fragile X syndrome, tuberous sclerosis complex and methyl CpG binding protein 2-related disorder, Dravet syndrome, and contactin-associated protein-like 2 (CNTNAP2) mutations or other knockout mice (reviewed in Buckley et al. 19 and Lee et al. 32 ). However, there is also increasing evidence that
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Early life events possibly underlying epilepsy and ASD Early life seizures can lead to both long-term changes in behavior and to increased neural excitability (but not necessarily epilepsy). Simple febrile seizures (>10 min) in infants appear to be relatively benign, but with complex febrile seizures (>30 min) there is an increased risk (up to eightfold) of developing epilepsy. 33, 34 Of interest, there is little evidence of adverse effects of simple febrile seizures on behavior. [35] [36] [37] It would be of interest to know what occurs after more complex seizures. A comprehensive review of neuropsychological impairment in childhood absence epilepsy identified numerous deficits, but no mention was made of ASD-like behaviors, although some deficits in language function were noted. 38 Animal models of early life seizures also reveal increased brain excitability into adulthood. Febrile or hyperthermic seizures in neonatal rats cause both long-term molecular changes as well as increased excitability [39] [40] [41] [42] and even epilepsy 43 in adulthood. Of interest, although there may be long-term alterations in emotional behavior, there is little evidence for ASD-like behavior in these experimental subjects.
In addition to febrile seizures, neonatal seizures occur in response to a variety of events, including neonatal hypoxia/ ischemia, hemorrhage, and strokes. Early life seizures can be modeled in rodents using convulsants, and there is compelling evidence for long-term effects on cognition. 19, 44 In addition, early life seizures were also found to cause deficits in some, but not all, ASD-like behaviors, largely revealed as deficits in social interactions. [45] [46] [47] It does not require as dramatic an intervention as a seizure to cause long-lasting alterations in brain function. In the rodent, postnatal central 48, 49 or peripheral activation of the immune system, 50,51 pre- 52 or postnatal 53, 54 stress, and maternal deprivation 55 all increase brain excitability into adulthood. Some of these interventions also lead to expression of ASD-like behaviors. 56, 57 Maternal immune activation and ASD A common experimental model of ASD is the maternal immune-activation model, which is based on observations that mothers experiencing viral infections at particular times during their pregnancy have increased risk of having children with ASD. 58, 59 In rodents, as well as other mammals including primates and pigs, an inflammatory stimulus given during mid-to late gestation to the dam also results in offspring displaying classic ASD-like symptoms (reviewed in Meyer 25 and Patterson 60 ). In this model, there are changes in both neuronal and synaptic function 61 as well as increased brain excitability, as revealed by lowered seizure threshold or enhanced susceptibility to kindling.
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Inflammation and epilepsy
An association of peripheral inflammation with seizure susceptibility or epilepsy is well recognized, and concurrent inflammation exacerbates seizure frequency in people with epilepsy. 65, 66 Animal models display a similar association, with rodent models of peripheral inflammatory bowel disease 67 and peripheral injection of the Toll-like receptor 4 ligand lipopolysaccharide (LPS) 41, 51 exacerbating seizure generation or enhancing seizure-induced injury in a number of seizure models.
Many types of peripheral inflammatory processes generate circulating inflammatory cytokines, but for the most part these do not appear to enter the brain. Rather, they create a 'mirror-like' inflammation in the brain through signaling via peripheral afferent nerves or at the blood-brain barrier to cause activation of microglial and other brain inflammatory cells that then synthesize de novo cytokines in the brain (reviewed in Riazi et al., 67 D'Mello and Swain, 68 and Konat 69 ). Pioneering work by Vezzani and others has established unequivocally that cytokines and other immune activators in the brain exacerbate brain excitability and seizure generation (reviewed in Vezzani et al. 70 ). Furthermore, inflammatory conditions and markers are also upregulated in virtually every animal seizure model studied (reviewed in Wilcox and Vezzani 71 and Devinsky et al. 72 ). Indeed, in a recent proteomic study, electrical stimulation-induced status epilepticus in rats resulted in enriched expression of up to 18 pathways (each including many inflammatory molecules and modulators) associated with the immune response and inflammation. 73 Although alterations in inflammatory processes may result from a seizure, it is important to note that a number of inflammatory molecules lower the threshold for seizure generation and increase seizure susceptibility. Thus any predisposing condition that elevates brain cytokines has the potential to increase seizure susceptibility.
Inflammation and ASD
Inflammation is also a feature of the brain in ASD. Microglia are upregulated 74 and cytokines and chemokines are increased in the cerebrospinal fluid or brain of individuals with ASD. 75 Although many genes are differentially expressed in ASD brains, it is noteworthy that those associated with immune and inflammatory responses are prominently figured. 76 This up-regulation of inflammatory markers and general inflammatory brain profile may be related to the fact that there appears to be a general dysregulation of the immune system toward a proinflammatory phenotype in ASD (reviewed in Meltzer and Van de Water 77 ). It appears likely that central nervous system (CNS) inflammation represents a common underlying mechanism for both epilepsy and ASD.
Priming the brain for later life susceptibility
A variety of interventions, including neonatal exposure to systemic LPS, 50 ,57,78 intracerebral ventricular infusion of Poly I:C, 48 and maternal separation 79 cause transient elevation of proinflammatory brain cytokines; even maternal immune activation elevates cytokine messenger RNA (mRNA) in the fetal brain, 80, 81 and some of the changes persist in offspring well into adulthood. 82 Because both microglia 83 and the cytokines they elaborate 84 play important roles in development, it is likely that a CNS milieu with elevated cytokine levels may undergo aberrant development that could lead to ASD in offspring. There is reasonable evidence that early life exposure to inflammation primes microglial cells so that they respond more vigorously to subsequent insults. 85 Thus subsequent exposure to a convulsive challenge in adulthood may result in exacerbated seizures and aberrant neural activity, for example arising from genetic mutation or insult that in itself would not normally lead to epilepsy but would do so in the "primed" brain. For either the fetus or the neonate, early life behavioral, 79, 86 physiologic, 87, 88 or environmental 89 adversity also cause elevation in CNS cytokines; the resultant priming could facilitate expression of both an ASD and an epileptic phenotype. Given the increasing realization of the role of the gut microbiota and perinatal diet in developmental programming of the CNS, 87, 88, 90, 91 and indications that it may have profound effects upon behavior, it will be interesting to see if it also affects brain excitability.
Some models of ASD show no epileptic phenotype. For example, mice with a mutation in the gene for neuroligin-3 display ASD-like behavior, yet display increased resistance to seizure generation. 92, 93 Another well-validated model of ASD, the BTBR mouse, 94 also does not display an epileptic phenotype. 24 It is possible that expression of both epilepsy and ASD may require coordinated action of more than one precipitating factor and that this is lacking in these models. For example, a recent study showed that imposition of maternal stress plus terbutaline (a ß2-adrenoreceptor agonist used to prevent preterm labor) resulted in emergence of an epilepsy-ASD phenotype, although neither intervention by itself was effective. 95 We have explored the possibility that an additional stressor that elevates CNS cytokines may facilitate emergence of an epilepsy phenotype in the BTBR mouse. Knowing that early life inflammation increases brain excitability, we have administered LPS to BTPR mouse pups and see not only increased brain excitability in adulthood, but also emergence of paroxysmal activity on EEG (authors' unpublished observations). If we were to relate this to children with ASD, one might speculate that the occurrence of an adverse series of events (infection, exposure to environmental toxins, early life stress) that initiate inflammation in the brain at a specific vulnerable age may lead to expression of both ASD and epilepsy in these individuals. Further work is necessary to explore this possibility in experimental models. In addition, epidemiologic studies in children with ASD and epilepsy may reveal possible linkages relating to early life conditions.
Role of Inflammation in Epilepsy-Associated Depression
(Andrey M. Mazarati) Depression is one of the most common comorbidities of epilepsy. Prevalence of depression among epilepsy patients is 30-50% versus 5-17% among people without epilepsy. 8 Depression has profound detrimental effects on the quality of life, ostensibly worse than seizures proper. Indeed, in patients with epilepsy, there is a parallel between depression and the severity of epilepsy, as well as with the resistance to antiepileptic drugs. 96, 97 Depression, including epilepsy-associated depression, is a multifactorial disease. Among many contemplated mechanisms, the role of inflammation in exacerbating or even precipitating depressive disorder has received overwhelming clinical and experimental support. 98, 99 Considering the critical role of inflammation in the pathophysiology of epilepsy, it is only logical to assume that inflammation may represent a causal link between the two disorders, thereby explaining the high degree of comorbidity between epilepsy and depression.
To understand the role of inflammation in epilepsy-associated depression, it would be instructive to first consider the role of inflammation in depression by and large, as it would provide useful insight into the epilepsy-depression connection. Although there are many possible ramifications of brain inflammation relevant to depression, here we focus on one aspect, that is, detrimental effects of inflammation on serotonergic transmission. Among many mechanisms of depression, serotonergic dysfunction has been best established. Multiple clinical and experimental studies show impairments in serotonergic transmission in depression, which occur on many levels, including serotonin (5-HT) synthesis, metabolism, release, as well as plasticity of 5-HT receptors. 100, 101 The evidence for the role of inflammation in depression comes mainly from two lines of observations, and in both cases the connection is bidirectional.
Proinflammatory pathways are activated in animal models of depression
Chronic inflammation is present in various animal models of depression. For example, prolonged forced swimming, which is a standard protocol to produce depressive phenotype in rodents, leads to the activation of microglia, as well as to the overexpression of such inflammatory cytokines as interleukin (IL)-6 and IL-1b in the hippocampus. 102 Depression induced by unpredictable chronic mild stress leads to the overexpression of IL-6 and IL-1b in prefrontal cortex, an area closely associated with pathophysiology of depression. 103 The evidence from genetic models is even more convincing. Thus 5-HT transporter heterozygous (SERT +/À ) rats, which present with depressive-like behavior, display both constitutive and inducible signs of inflammation. Particularly, these animals have constitutively upregulated IL-1b and CD112b in the hippocampus, and respond with the exacerbated activation of hippocampal IL-6 upon LPS challenge. 104 Another validated model of depression, Flinders sensitive rats, show multiple markers of peripheral and central inflammation, either constitutive (e.g., increased IL-1a, decreased CRP) or inducible (e.g., long-lasting exacerbated increase in apolipoprotein-E, a1-macroglubulin, and complement C3 upon early life stress). 105 Animal models of inflammation are characterized by depressive-like phenotype
Conversely, animal models of inflammation consistently produce depressive-like phenotype in rodents. Depressive behaviors have been widely reported under conditions of Gram-negative infections, mimicked by LPS, 106, 107 as well as under conditions of viral-like infections mimicked by Poly:IC. 108, 109 Autoimmune diseases and animal models thereof are commonly associated with depressive behaviors. This has been reported for rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. [110] [111] [112] Furthermore, direct administration of a single recombinant inflammatory cytokine, such as interferon a (IFN-a) , IL-1b, or tumor necrosis factor a (TNF-a) is sufficient to induce the full spectrum of depressive behavior. [113] [114] [115] Such redundancy in the ability of various components of innate immune response to induce depressive impairments may explain why depression is a common consequence of inflammatory processes independent of the etiology.
Inflammation disrupts serotonergic transmission
Inflammation directly affects 5-HT metabolism and transmission; several cytokines have been implicated (e.g., IL-1b, IL-6, and TNF-a). In raphe nuclei, IL-b inhibits tryptophan hydroxylase (TPH) and activates indoleamine 2,3-dioxygenase (IDO). 107, [116] [117] [118] The significance of these effects is related to tryptophan metabolism. TPH is involved in the rate-limiting step of 5-HT synthesis from tryptophan; thus disruption of TPH by inflammatory mediators would lead to the suppression of 5-HT synthesis. IDO catalyzes the rate-limiting step in the alternative, kynurenine pathway of tryptophan metabolism. Therefore, the activation of IDO would lead to 5-HT insufficiency due to the limited availability of substrate for TPH. Furthermore, quinolinic acid, which is a penultimate metabolite in the kynurenine pathway, is a neurotoxin 119 ; its accumulation in raphe nuclei secondary to the IDO activation is likely to contribute to excitotoxic loss of serotonergic neurons.
In addition to metabolic effects, cytokines, particularly IL-1b, directly inhibit the firing of serotonergic neurons, 120 the result being the suppressed serotonergic tone in raphe nuclei efferents projecting to the hippocampus and prefrontal cortex.
Thus mediators of inflammation disrupt serotonergic transmission on several levels, which may explain the high degree of comorbidity between inflammation and depression.
Experimental therapy studies: anti-inflammatory drugs exert antidepressant effects
Multiple studies have established the antidepressant effects of anti-inflammatory drugs. Three types of drugs have been most extensively explored: COX-2 inhibitors (e.g., celecoxib), minocycline (an inhibitor of microglia), and anakinra (IL-1R1 receptor antagonist) exert versatile antidepressant effects in various depression paradigms. For example, celecoxib attenuated the dysregulation of the hypothalamopituitary-adrenocortical axis (HPA-A) induced by olfactory bulbectomy, and anhedonia induced by unpredictable chronic mild stress. 121, 122 Minocycline normalized animals' behavior in the learned helplessness and forced swimming depression models. 123, 124 Anakinra improved symptoms of depression induced in rats by LPS and by unpredictable chronic mild stress. 125, 126 Antidepressant drugs act as anti-inflammatory agents Conversely, in animal models of inflammation, antidepressant drugs appear to possess truly anti-inflammatory properties. Anti-inflammatory effects have been established for different classes of antidepressants, including selective serotonin reuptake inhibitors (SSRIs; such as sertraline and citalopram), tricyclic antidepressants (e.g., desipramine and imipramine), and atypical antidepressants (such as agomelatine, a melatonin receptor inhibitor). [127] [128] [129] The exact mechanisms of these effects remain unknown; the most widely held view is the elevation of intracellular cyclic AMP levels and resulting from this, the inhibition of astroglia and microglia. 130 Direct suppression of inflammatory mediators, particularly cytokines, has also been shown. 131 
Role of inflammation in epilepsy-associated depression
Animals with chronic epilepsy typically develop depressive-like behavioral impairments, such as anhedonia and hopelessness/despair. 132 These behavioral deficits develop due to perturbations in serotonergic transmission in pathways ascending from raphe nuclei into the forebrain (particularly the hippocampus and prefrontal cortex). 132 Suppressed serotonergic tone in raphe nuclei efferents in turn may occur as a result of the upregulation of 5-HT1A autoreceptors and subsequent increased autoinhibition of 5-HT release. 133 Furthermore, it has been established that the upregulation of 5-HT1A autoreceptors is driven by the hyperactive HPA-A, which in itself is induced by the chronic elevation of IL-1b in the epileptic hippocampus. 
Epilepsy-associated depression is amenable to antiinflammatory interventions
Similarly to other depressions, epilepsy-associated depression may be improved by anti-inflammatory drugs. For example, in chronic epileptic rats, minocycline attenuated signs of anhedonia and despair/hopelessness, presumably via the inhibition of IDO. 135 Chronic infusion of anakinra into the hippocampus of rats with chronic epilepsy attenuated signs of both despair/hopelessness and anhedonia, and improved serotonergic tone in raphe-forebrain afferents. 134 There is some evidence that antidepressant drugs can attenuate seizure-induced inflammation.
Inflammation and resistance to antidepressants
Resistance to antidepressants represents a major challenge in the management of depression. Particularly, SSRIs, although being the most effective antidepressant drugs to date, are effective in only about half of patients with depression. 136 Various mechanisms of SSRI resistance have been discussed, including single nucleotide polymorphisms (SNPs). From the inflammation perspective, several studies tied the SSRI resistance to SNP in genes encoding IL-1b and IL-6. 137, 138 Anti-inflammatory drugs improve the effectiveness of antidepressants. For example, combined treatment with a COX-2 (celecoxib) and an SSRI (fluoxetine) dramatically increased 5-HT release from prefrontal cortex as compared with respective monotherapies. 139 In rats with chronic epilepsy and concurrent depression, all of the following are SSRI resistant: behavior, serotonergic transmission, and HPA-A function. At the same time, combining fluoxetine with low dose anakinra resulted in strong antidepressant effects. The synergism between the two types of drugs was explained by disruption of the sustained inflammatory drive from the hippocampus on HPA-A and downstream on 5-HT1A autoreceptors. 140 
Conclusion and Future Directions
We have provided evidence of a critical role for inflammation in the genesis of epilepsy and two of its common psychiatric comorbidities (Fig. 1) . However, further research is needed. It is interesting that brain excitability and ASD-like behaviors are well known to be increased by early life inflammation, but this has been less well studied in depression. With respect to the association of epilepsy and depression, this would appear to be a potential avenue for further research. In addition, there is still little understanding of why some people with ASD will have epilepsy and others will not; it is possible that studies in animal models of ASD, such as the maternal immune-activation model combined with imposition of immune, behavioral, or environmental stressors may reveal interactions that have their basis in common inflammatory pathways. Likewise, the high comorbidity between epilepsy and depression can be partially understood by the fact that inflammatory processes may contribute to both. It is likely that anti-inflammatory therapy has real potential in controlling both epilepsy and some of these behavioral comorbidities. 
